• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Presale: Japan Housing Finance Agency Nov 10 Product Image

Presale: Japan Housing Finance Agency Nov 10

  • ID: 2049873
  • November 2010
  • Region: Japan
  • Standard & Poors

Standard & Poor's Ratings Services expects to assign its 'AAA (sf)' rating to Japan Housing Finance Agency's (JHF) -183.4 billion series 42 fixed-rate residential mortgage-secured pass-through notes and beneficiary certificates (subsequent to a trigger event). Standard & Poor's rating addresses the full and timely payment of interest, or interest distribution in the case of the beneficiary certificates, allowing for a three-month grace period, and the ultimate repayment of principal by the transaction's legal final maturity in November 2045. The preliminary rating is based on information as of Oct. 20, 2010. Subsequent information may result in the assignment of a final rating that differs from the preliminary rating. Final ratings will be assigned after the amount and exact terms are finalized...

Companies mentioned in this report are: Japan Housing Finance Agency

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown

Japan Housing Finance Agency

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Fluidigm Corporation Apple, Inc. CEVA Santé Animale Abbott Laboratories Ltd. Merck Group Allergan Inc. Pfizer, Inc.